The growth of the EPS is critical in understanding the current valuation of Aeterna Zentaris. It is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 1836.50 % over the last twelve months. EPS growth is a vital measure of execution of the strategy for Aeterna Zentaris since it indicates how well the business is allocating resources to benefit shareholders.



Aeterna Zentaris is in the healthcare sector and is in the biotechnology industry. The company CEO is Michael Ward. AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing novel treatments in oncology, endocrinology and women’s health.

Previous Intraday Performance:

The AEZS shares had a previous change of 6.34% which opened at 3.50 and closed at 3.69. It moved to an intraday high of 3.89 and a low of 3.50.

SeekingAlpha:  Story Starting To Change For AEterna Zentaris

Historical Performance:

Over the last five trading days, AEZS shares returned 5.73% and in the past 30 trading days it returned 20.59%. Over three months, it changed 142.76%. In one year it has changed 78.26% and within that year its 52-week high was 3.92 and its 52-week low was 1.12. AEZS stock is 229.46% above its 52 Week Low.

Our calculations result in a 200 day moving average of 2.06 and a 50 day moving average of 2.84. Right now, AEZS stock is trading 79.46% above its 200 day moving average.

SeekingAlpha:  Story Starting To Change For AEterna Zentaris

Liquidity:

The company has a market cap of $60.7m with 16.4m shares outstanding and a float of 16.4m shares. Trading volume was 650,162 shares and has experienced an average volume of 367,788 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Aeterna Zentaris was -1.09 which ended on 31st of December 2017. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.25.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.15
06-30-2018:  -0.16
03-31-2018:  0.87
12-31-2017:  -0.24



Base on our calculations, the intrinsic value per share is 6.94, which means it might be undervalued and has a margin of safety of 46.83%

Indicators Also to Watch:

Based on the latest filings, there is 4.90% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.

I calculated the beta to be 1.02

Business Wire:  Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is 323.70%, return on assets is 34.62%, profit margin is 36.54%, price-to-sales is 1.73 and price-to-book is 8.23.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 4  : Past Performance Result
 4  : Valuation Result
 0  : Dividend Safety Result
 3  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here